Table 2.
Mt DNA haplogroups | Unadjusted analysis* | Adjusted analysis** | |||
---|---|---|---|---|---|
No | Yes | p-value | aAMR (95% CI) | p-value | |
Clusters or major haplogroups | |||||
HV | 9.1 (5.5; 14) | 10 (6.4; 14.7) | 0.288 | 0.98 (0.86; 1.13) | 0.839 |
U | 9.8 (6.2; 14.1) | 9.1 (5.1; 13.9) | 0.321 | 0.91 (0.77; 1.08) | 0.300 |
JT | 9.8 (6.2; 14) | 9.2 (5.6; 13.6) | 0.765 | 1.12 (0.94; 1.33) | 0.205 |
Haplogroups | |||||
H | 9.1 (5.6; 13.7) | 10.2 (6.9; 14.1) | 0.075 | 1.04 (0.91; 1.21) | 0.544 |
J | 9.8 (6.2; 14) | 8.8 (5.2; 12.2) | 0.522 | 1.07 (0.86; 1.32) | 0.537 |
T | 9.6 (6.1; 14) | 9.7 (6.8; 14.2) | 0.735 | 1.17 (0.90; 1.51) | 0.225 |
HIV human immunodeficiency virus, aAMR adjusted arithmetic mean ratio, CI confidence interval
Statistical: * Values were expressed as median (cells/mm3/month) (percentile 25; percentile 75). p-values were calculated by Mann–Whitney tests. ** Values were expressed as adjusted arithmetic mean ratio (aAMR) and 95% of confidence interval (95% CI) of the slopes of CD4+ T-cells recovery (cells/mm3/month). p-values were calculated by Generalized Linear Models test with a normal distribution (log-link). These regressions were adjusted by the most important clinical and epidemiological characteristics (gender, age, length of HIV-infection, baseline CD4+ cells/mm3, HIV transmission route related to IDU, hepatitis C and hepatitis B coinfection, and type of cART regimen)